Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 2, 2012, Pages 288-293

  Puglia, Carmelo ^a   Frasca, Giuseppina ^a   Musumeci, Teresa ^a   Rizza, Luisa ^a   Puglisi, Giovanni ^a   Bonina, Francesco ^a   Chiechio, Santina ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

CNS; Curcumin; Motor toxicity evaluation; Nanostructured lipid carrier (NLC); P300 acetyltransferase inhibitor; Western blot analysis

Indexed keywords

CURCUMIN; DRUG CARRIER; HISTONE ACETYLTRANSFERASE; HISTONE H4; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; HISTONE ACETYLATION; HISTONE HYPOACETYLATION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; ROTAROD TEST; SPINAL CORD; WESTERN BLOTTING; ZETA POTENTIAL;

ACETYLATION; ANIMALS; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG CARRIERS; DRUG STABILITY; HISTONE ACETYLTRANSFERASES; HISTONES; INJECTIONS, INTRAPERITONEAL; LIPIDS; MALE; MICE; NANOSTRUCTURES; PARTICLE SIZE;

EID: 84861634891     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.03.015     Document Type: Article

References (38)

1. B.B. Aggarwal, and K.B. Harikumar Potential therapeutic effects of cur-cumin, the anti inflammatory agent, against neurodegenerative, cardio-vascular, pulmonary, metabolic, autoimmune and neoplastic diseases Int. J. Biochem. Cell. Biol. 41 2009 40 59
2. B.B. Aggarwal, and B. Sung Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets Trends Pharmacol. Sci. 30 2009 85 94
3. J. Miquel, A. Bernd, J.M. Sempere, J. Diaz-Alperi, and A. Ramirez The curcuma antioxidants: pharmacological effects and prospects for future clinical use Arch. Gerontol. Geriatr. 34 2002 37 46
4. K. Balasubramanyam, R.A. Varier, M. Altaf, V. Swaminathan, N.B. Siddappa, S.U. Ranga, and T.K. Kundu Curcumin, a novel p300/CREB-binding protein - specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription J. Biol. Chem. 279 2004 51163 51171
5. A. Mai, D. Rotili, D. Tarantino, P. Ornaghi, F. Tosi, C. Vicidomini, G. Sbardella, A. Nebbioso, M. Miceli, L. Altucci, and P. Filetici Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties J. Med. Chem. 49 2006 6897 6907
6. T. Morimoto, Y. Sunagawa, T. Kawamura, T. Takaya, H. Wada, A. Nagasawa, M. Komeda, M. Fujita, A. Shimatsu, T. Kita, and K. Hasegawa The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats J. Clin. Invest. 118 2008 868 878
7. K. Luger, A.W. Mäder, R.K. Richmond, D.F. Sargent, and T.J. Richmond Crystal structure of the nucleosome core particle at 2.8 a resolution Nature 389 1997 251 260
8. G. Felsenfeld, and M. Groudine Controlling the double helix Nature 421 2003 448 453
9. T. Jenuwein, and C.D. Allis Translating the histone code Science 293 2001 1074 1080
10. J.R. Davie, and V.A. Spencer Control of histone modifications J. Cell. Biochem. S32-S33 1999 141 148
11. K.P. Nightingale, L.P. O'Neill, and B.M. Turner Histone modifications: signaling receptors and potential elements of a heritable epigenetic code Curr. Opin. Genet. Dev. 16 2006 125 136
12. S.R. Bhaumik, E. Smith, and A. Shilatifard Covalent modifications of histones during development and disease pathogenesis Nat. Struct. Mol. Biol. 14 2007 1008 1016
13. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
14. F.J. Dekker, and H.J. Haisma Histone acetyl transferases as emerging drug targets Drug Discov. Today 14 2009 942 948
15. X.J. Yang, and E. Seto HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention Oncogene 26 2007 5310 5318
16. S.Y. Roth, J.M. Denu, and C.D. Allis Histone acetyltransferases Ann. Rev. Biochem. 70 2001 81 120
17. H. Ogiwara, A. Ui, A. Otsuka, H. Satoh, I. Yokomi, S. Nakajima, A. Yasui, J. Yokota, and T. Kohno Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors Oncogene 30 2011 2135 2146
18. B.D. Strahl, and C.D. Allis The language of covalent histone modifications Nature 403 2000 41 45
19. D. Herman, K. Jenssen, R. Burnett, E. Soragni, S.L. Perlman, and J.M. Gottesfeld Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia Nat. Chem. Biol. 2 2006 551 558
20. S. Peleg, F. Sananbenesi, A. Zovoilis, S. Burkhardt, S. Bahari-Javan, R.C. Agis-Balboa, P. Cota, J.L. Wittnam, A. Gogol-Doering, L. Opitz, G. Salinas-Riester, M. Dettenhofer, H. Kang, L. Farinelli, W. Chen, and A. Fischer Altered histone acetylation is associated with age-dependent memory impairment in mice Science 328 2010 753 756
21. J. Kang, J. Chen, Y. Shi, J. Jia, and Y. Zhang Curcumin-induced histone hypoacetylation: the role of reactive oxygen species Biochem. Pharmacol. 69 2005 1205 1213
22. H. Sun, X. Yang, J. Zhu, T. Lv, Y. Chen, G. Chen, L. Zhong, Y. Li, X. Huang, G. Huang, and J. Tian Inhibition of p300-HAT results in a reduced histone acetylation and down-regulation of gene expression in cardiac myocytes Life Sci. 87 2010 707 714
23. M.H. Pan, T.M. Huang, and J.K. Lin Biotransformation of curcumin through reduction and glucuronidation in mice Drug Metab. Dispos. 27 1999 486 494
24. R.H. Müller, M. Radtke, and S.A. Wissing Nanostructured lipid matrices for improved microencapsulation of drugs Int. J. Pharm. 242 2002 121 128
25. M.D. Joshi, and R.H. Müller Lipid nanoparticles for parenteral delivery of actives Eur. J. Pharm. Biopharm. 71 2009 161 172
26. F. Feng, D. Zheng, D. Zhang, C. Duan, Y. Wang, L. Jia, F. Wang, Y. Liu, Q. Gao, and Q. Zhang Preparation, characterization and biodistribution of nanostructured lipid carriers for parenteral delivery of bifendate J. Microencapsul. 28 2011 280 285
27. D. Liu, Z. Liu, L. Wang, C. Zhang, and N. Zhang Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel Colloids Surf. B Biointerfaces 85 2011 262 269
28. C. Puglia, M.G. Sarpietro, F. Bonina, F. Castelli, M. Zammataro, and S. Chiechio Development, characterization, and in vitro and in vivo evaluation of benzocaine- and lidocaine-loaded nanostructrured lipid carriers J. Pharm. Sci. 100 2011 1892 1899
29. A.P. Nayak, W. Tiyaboonchai, S. Patankar, B. Madhusudhan, and E.B. Souto Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment Colloids Surf. B Biointerfaces 81 2010 263 273
30. S. Chiechio, M. Zammataro, M.E. Morales, C.L. Busceti, F. Drago, R.W. 4th Gereau, A. Copani, and F. Nicoletti Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain Mol. Pharmacol. 75 2009 1014 1020
31. W. Tiyaboonchai, W. Tungpradit, and P. Plianbangchang Formulation and characterization of curcuminoids loaded solid lipid nanoparticles Int. J. Pharm. 337 2007 299 306
32. R.S. Mulik, J. Mönkkönen, R.O. Juvonen, K.R. Mahadik, and A.R. Paradkar Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis Int. J. Pharm. 398 2010 190 203
33. F. Castelli, C. Puglia, M.G. Sarpietro, L. Rizza, and F. Bonina Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry Int. J. Pharm. 304 2005 231 238
34. N.W. Dunham, and T.S. Miya A note on a simple apparatus for detecting neurological deficit in rats and mice J. Am. Pharm. Assoc. (Baltim) 46 1957 208 209
35. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S.C. Berghs, N. Carey, P.W. Finn, L.S. Collins, A. Tumber, J.W. Ritchie, P.B. Jensen, H.S. Lichenstein, and M. Sehested Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem. J. 409 2008 581 589
36. M.C. Myzak, and R.H. Dashwood Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane Curr. Drug Targets 7 2006 443 452
37. J.M. Hooker, S.W. Kim, D. Alexoff, Y. Xu, C. Shea, A. Reid, N. Volkow, and J.S. Fowler Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using positron emission tomography ACS Chem. Neurosci. 1 2010 65 73
38. M. Ghizzoni, H.J. Haisma, H. Maarsingh, and F.J. Dekker Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation Drug Discov. Today 2011 504 511